ArticlePloS one2011
Budesonide and formoterol reduce early innate anti-viral immune responses in vitro.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- The association between inhaled corticosteroid and the risks of SARS-COV-2 infection: A systematic review and meta-analysis.Journal of infection and public health · 2023Pooled it
- Rhinovirus-Induced Cytokine Alterations With Potential Implications in Asthma Exacerbations: A Systematic Review and Meta-Analysis.Frontiers in immunology · 2022Pooled it
- Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective.The European respiratory journal · 2020Pooled it
- Dendritic cells from aged subjects contribute to chronic airway inflammation by activating bronchial epithelial cells under steady state.Mucosal immunology · 2014Trial
- Differential TLR-ERK1/2 Activity Promotes Viral ssRNA and dsRNA Mimic-Induced Dysregulated Immunity in Macrophages.Pathogens (Basel, Switzerland) · 2024Article
- Is using inhaled corticosteroid effective against COVID-19 pneumonia severity and mortality?Tuberkuloz ve toraks · 2024Observational
- Differential TLR-ERK1/2 activity promotes viral ssRNA and dsRNA mimic-induced dysregulated immunity in macrophages.bioRxiv : the preprint server for biology · 2024Article
- Effects of treatment with corticosteroids on human rhinovirus-induced asthma exacerbations in pediatric inpatients: a prospective observational study.BMC pulmonary medicine · 2023Observational
- Expression of circulating angiotensin-converting enzyme 2 in children with asthma and the effects of inhaled corticosteroids.Immunity, inflammation and disease · 2023Article
- Regular Inhaled Corticosteroids Use May Protect Against Severe COVID-19 Outcome in COPD.International journal of chronic obstructive pulmonary disease · 2023Article
- Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19.Scientific reports · 2022Article
- Impact of COVID-19 in Children with Chronic Lung Diseases.International journal of environmental research and public health · 2022Review
- Impact of Coronavirus Disease 2019 on the Pediatric Population with Aerodigestive Disease.The Journal of pediatrics · 2022Article
- SARS-CoV-2-Specific Adaptive Immunity in COVID-19 Survivors With Asthma.Frontiers in immunology · 2022Article
- COVID-19 and COPD: lessons beyond the pandemic.American journal of physiology. Lung cellular and molecular physiology · 2021Article
- Antiviral Effect of Budesonide against SARS-CoV-2.Viruses · 2021Article
- Beneficial Immunomodulatory Effects of Fluticasone Propionate inPathogens (Basel, Switzerland) · 2021Article
- Asthma and COVID-19: Emphasis on Adequate Asthma Control.Canadian respiratory journal · 2021Review
- Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review.SN comprehensive clinical medicine · 2020Review
- Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations.Nature communications · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a chronic inflammatory airways disease in which respiratory viral infections frequently trigger exacerbations. Current treatment of asthma with combinations of inhaled corticosteroids and long acting beta2 agonists improves asthma control and reduces exacerbations but what impact this might have on innate anti-viral immunity is unclear. We investigated the in vitro effects of asthma drugs on innate anti-viral immunity. Peripheral blood mononuclear cells (PBMC) from healthy and asthmatic donors were cultured for 24 hours with the Toll-like receptor 7 agonist, imiquimod, or rhinovirus 16 (RV16) in the presence of budesonide and/or formoterol. Production of proinflammatory cytokines and expression of anti-viral intracellular signalling molecules were measured by ELISA and RT-PCR respectively. In PBMC from healthy donors, budesonide alone inhibited IP-10 and IL-6 production induced by imiquimod in a concentration-dependent manner and the degree of inhibition was amplified when budesonide and formoterol were used in combination. Formoterol alone had little effect on these parameters, except at high concentrations (10⁻⁶ M) when IL-6 production increased. In RV16 stimulated PBMC, the combination of budesonide and formoterol inhibited IFNα and IP-10 production in asthmatic as well as healthy donors. Combination of budesonide and formoterol also inhibited RV16-stimulated expression of the type I IFN induced genes myxovirus protein A and 2', 5' oligoadenylate synthetise. Notably, RV16 stimulated lower levels of type Myxovirus A and oligoadenylate synthase in PBMC of asthmatics than control donors. These in vitro studies demonstrate that combinations of drugs commonly used in asthma therapy inhibit both early pro-inflammatory cytokines and key aspects of the type I IFN pathway. These findings suggest that budesonide and formoterol curtail excessive inflammation induced by rhinovirus infections in patients with asthma, but whether this inhibits viral clearance in vivo remains to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.